1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients
| Autor: | Veluswamy, R., Bhalla, S., Samstein, R., Marron, T., Gomez, J.E., Doroshow, D.B., Sabari, J., Shum, E., Saxena, A., Namakydoust, A., Chachoua, A., Wisnivesky, J., Mandeli, J., Bhardwaj, N., Hirsch, F.R., Merad, M., Reddy, E. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1019-S1020 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|